Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meprobamate
Drug ID BADD_D01390
Description A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
Indications and Usage For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Marketing Status approved; illicit
ATC Code N05BC01
DrugBank ID DB00371
KEGG ID D00376
MeSH ID D008620
PubChem ID 4064
TTD Drug ID D0Y4AW
NDC Product Code 62332-019; 46708-019; 69097-974; 66022-0105; 46708-020; 66064-4001; 51672-4148; 62332-020; 69097-975; 51672-4147
UNII 9I7LNY769Q
Synonyms Meprobamate | Miltown | Méprobamate Richard | Meprospan | Tranmep | Visano | Equanil | Dapaz
Chemical Information
Molecular Formula C9H18N2O4
CAS Registry Number 57-53-4
SMILES CCCC(C)(COC(=O)N)COC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Accommodation disorder06.02.04.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anuria20.01.03.002--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Chills08.01.09.001; 15.05.03.016--
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 02.11.04.006; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electroencephalogram abnormal13.07.03.001--Not Available
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
The 1th Page    1 2 3    Next   Last    Total 3 Pages